NASDAQ:EVFMEvofem Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evofem Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.92 -0.05 (-1.68 %) (As of 07/14/2020 09:48 AM ET) Add Compare Share Today's Range$2.89Now: $2.92▼$2.9950-Day Range$2.78MA: $3.50▼$5.9352-Week Range$2.73Now: $2.92▼$7.50Volume359,514 shsAverage Volume3.68 million shsMarket Capitalization$145.15 millionP/E RatioN/ADividend YieldN/ABeta0.41 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingEvofem Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Evofem Biosciences has a potential upside of 311.0% from its current price of $2.92.Amount of Analyst CoverageEvofem Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesEvofem Biosciences has received 248 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEvofem Biosciences has received 205 “underperform” votes. (Add your “underperform” vote.)Community SentimentEvofem Biosciences has received 54.75% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote “Outperform” if you believe EVFM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEvofem Biosciences does not currently pay a dividend.Dividend GrowthEvofem Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evofem Biosciences insiders have bought 575.09% more of their company's stock than they have sold. Specifically, they have bought $3,028,481.00 in company stock and sold $448,603.00 in company stock.Percentage Held by InsidersOnly 9.40% of the stock of Evofem Biosciences is held by insiders.Percentage Held by Institutions56.68% of the stock of Evofem Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Evofem Biosciences are expected to grow in the coming year, from ($1.80) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evofem Biosciences is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evofem Biosciences is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvofem Biosciences has a P/B Ratio of 8.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.37 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVFM Previous Symbol CUSIPN/A CIK1618835 Webwww.evofem.com Phone858-550-1900Debt Debt-to-Equity RatioN/A Current Ratio0.95 Quick Ratio0.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book8.85Profitability EPS (Most Recent Fiscal Year)($1.31) Net Income$-80,030,000.00 Net MarginsN/A Return on Equity-304.11% Return on Assets-169.44%Miscellaneous Employees30 Outstanding Shares49,710,000Market Cap$145.15 million Next Earnings Date8/3/2020 (Estimated) OptionableNot Optionable NASDAQ:EVFM Rates by TradingView Receive EVFM News and Ratings via Email Sign-up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions How has Evofem Biosciences' stock been impacted by COVID-19 (Coronavirus)? Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EVFM stock has decreased by 43.4% and is now trading at $2.92. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Evofem Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evofem Biosciences. When is Evofem Biosciences' next earnings date? Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Evofem Biosciences. How were Evofem Biosciences' earnings last quarter? Evofem Biosciences Inc (NASDAQ:EVFM) released its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.08. View Evofem Biosciences' earnings history. What price target have analysts set for EVFM? 5 Wall Street analysts have issued 12-month price targets for Evofem Biosciences' shares. Their forecasts range from $6.00 to $25.00. On average, they anticipate Evofem Biosciences' share price to reach $12.00 in the next year. This suggests a possible upside of 311.0% from the stock's current price. View analysts' price targets for Evofem Biosciences. Has Evofem Biosciences been receiving favorable news coverage? Press coverage about EVFM stock has trended somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evofem Biosciences earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Evofem Biosciences. Who are some of Evofem Biosciences' key competitors? Some companies that are related to Evofem Biosciences include Atreca (BCEL), Ardelyx (ARDX), Collegium Pharmaceutical (COLL), Legend Biotech (CALT), Kala Pharmaceuticals (KALA), AnaptysBio (ANAB), Molecular Templates (MTEM), Athersys (ATHX), Syros Pharmaceuticals (SYRS), Syndax Pharmaceuticals (SNDX), Corbus Pharmaceuticals (CRBP), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), NextCure (NXTC) and Clovis Oncology (CLVS). View all competitors. What other stocks do shareholders of Evofem Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include Anavex Life Sciences (AVXL), Momo (MOMO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Nabriva Therapeutics (NBRV), Catalyst Pharmaceuticals (CPRX), Interpace Diagnostics Group (IDXG) and Marinus Pharmaceuticals (MRNS). Who are Evofem Biosciences' key executives? Evofem Biosciences' management team includes the following people: Ms. Saundra Pelletier, CEO & DirectorMr. Justin J. File, Chief Financial Officer (Age 49)Dr. Kelly Culwell, Chief Medical OfficerMr. Jason Abrams, Accounting Mang.Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52) What is Evofem Biosciences' stock symbol? Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM." How do I buy shares of Evofem Biosciences? Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Evofem Biosciences' stock price today? One share of EVFM stock can currently be purchased for approximately $2.92. How big of a company is Evofem Biosciences? Evofem Biosciences has a market capitalization of $145.15 million. The biotechnology company earns $-80,030,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe. What is Evofem Biosciences' official website? The official website for Evofem Biosciences is www.evofem.com. How can I contact Evofem Biosciences? Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
